Skip to content

Tiziana nabs new U.S. patent for expanded use of Foralumab

August 18, 2020

Tiziana Life Sciences (NASDAQ:TLSA) soars 26% premarket on the heels of the announcement that the USPTO has granted the company a patent on use and methods of treatment of Crohn’s disease with Foralumab, a fully human monoclonal antibody, and all other anti-CD3 monoclonal antibodies (mAb).

The composition-of-matter and use patent will be published on September 1 as Patent No. 10,759,858.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: